Literature DB >> 2565620

Complement activation in amyloid plaques in Alzheimer's dementia.

P Eikelenboom1, C E Hack, J M Rozemuller, F C Stam.   

Abstract

Amyloid plaques in Alzheimer's dementia contain complement factors C1q, C4 and C3. In the present study we demonstrate complement activation in amyloid plaques using immunoenzymatical techniques and specific antibodies against subunits of individual complement components and activated complement products. Amyloid plaques contain C1q and activated C3 fragments (C3c and C3d, g) but no C1s and C3a. These findings demonstrate that the complement components are not passively bound to the amyloid plaque structures but are the result of an activation process. The role of complement activation in the genesis of senile plaques is discussed.

Entities:  

Mesh:

Year:  1989        PMID: 2565620     DOI: 10.1007/BF02890024

Source DB:  PubMed          Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol        ISSN: 0340-6075


  69 in total

1.  Microglia in Alzheimer's disease and transgenic models. How close the fit?

Authors:  D W Dickson
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

Review 2.  Roles of the complement system in human neurodegenerative disorders: pro-inflammatory and tissue remodeling activities.

Authors:  Philippe Gasque; Jim W Neal; Sim K Singhrao; Eamon P McGreal; Yann D Dean; Beek Johan Van; B Paul Morgan
Journal:  Mol Neurobiol       Date:  2002-02       Impact factor: 5.590

Review 3.  Local neuroinflammation and the progression of Alzheimer's disease.

Authors:  Patrick L McGeer; Edith G McGeer
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

4.  Charge-based binding of complement component C1q to the Alzheimer amyloid beta-peptide.

Authors:  S Webster; B Bonnell; J Rogers
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

Review 5.  Alzheimer's silent partner: cerebral amyloid angiopathy.

Authors:  Tanya L Cupino; Matthew K Zabel
Journal:  Transl Stroke Res       Date:  2013-11-19       Impact factor: 6.829

6.  Lipopolysaccharide endotoxemia induces amyloid-β and p-tau formation in the rat brain.

Authors:  Li-Ming Wang; Qi Wu; Ryan A Kirk; Kevin P Horn; Ahmed H Ebada Salem; John M Hoffman; Jeffrey T Yap; Joshua A Sonnen; Rheal A Towner; Fernando A Bozza; Rosana S Rodrigues; Kathryn A Morton
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-04-25

Review 7.  Therapeutic implications of the prostaglandin pathway in Alzheimer's disease.

Authors:  Eiron Cudaback; Nikolas L Jorstad; Yue Yang; Thomas J Montine; C Dirk Keene
Journal:  Biochem Pharmacol       Date:  2014-01-13       Impact factor: 5.858

8.  Distribution of neuronal growth-promoting factors and cytoskeletal proteins in altered neurites in Alzheimer's disease and non-demented elderly.

Authors:  S S Zhan; W Kamphorst; W E Van Nostrand; P Eikelenboom
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

9.  Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice.

Authors:  Marcel Maier; Ying Peng; Liying Jiang; Timothy J Seabrook; Michael C Carroll; Cynthia A Lemere
Journal:  J Neurosci       Date:  2008-06-18       Impact factor: 6.167

10.  Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis.

Authors:  G A Tennent; L B Lovat; M B Pepys
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.